160 related articles for article (PubMed ID: 24304203)
1. Raltegravir as antiretroviral therapy in HIV/AIDS.
Sharma M; Walmsley SL
Expert Opin Pharmacother; 2014 Feb; 15(3):395-405. PubMed ID: 24304203
[TBL] [Abstract][Full Text] [Related]
2. Role of raltegravir in HIV-1 management.
Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
[TBL] [Abstract][Full Text] [Related]
3. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
4. Treatment of HIV infection with raltegravir.
Chirch LM; Morrison S; Steigbigel RT
Expert Opin Pharmacother; 2009 May; 10(7):1203-11. PubMed ID: 19385721
[TBL] [Abstract][Full Text] [Related]
5. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
Calcagno A; D'Avolio A; Bonora S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1167-76. PubMed ID: 26073580
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir: an integrase inhibitor for HIV-1.
Evering TH; Markowitz M
Expert Opin Investig Drugs; 2008 Mar; 17(3):413-22. PubMed ID: 18321239
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dolutegravir safety for the treatment of HIV-1.
Keeshin SW; Feinberg J
Expert Opin Drug Saf; 2015 Jan; 14(1):141-7. PubMed ID: 25347230
[TBL] [Abstract][Full Text] [Related]
10. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
Evering TH; Markowitz M
Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
[TBL] [Abstract][Full Text] [Related]
12. Integrase inhibitors in the treatment of HIV-1 infection.
Powderly WG
J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of raltegravir: from healthy volunteers to phase III trials].
Gatell JM
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():29-33. PubMed ID: 19572423
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of raltegravir in HIV/AIDS.
Chaudhary MA; Elbasha EH; Kumar RN; Nathanson EC
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):627-39. PubMed ID: 22098278
[TBL] [Abstract][Full Text] [Related]
16. HIV integrase inhibitors: a new era in the treatment of HIV.
Blanco JL; Whitlock G; Milinkovic A; Moyle G
Expert Opin Pharmacother; 2015 Jun; 16(9):1313-24. PubMed ID: 26001181
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir: in treatment-naive patients with HIV-1 infection.
Croxtall JD; Scott LJ
Drugs; 2010 Mar; 70(5):631-42. PubMed ID: 20329808
[TBL] [Abstract][Full Text] [Related]
18. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
19. A safety evaluation of raltegravir for the treatment of HIV.
de Miguel R; Montejano R; Stella-Ascariz N; Arribas JR
Expert Opin Drug Saf; 2018 Feb; 17(2):217-223. PubMed ID: 29199485
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
